Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Purpose of review The cardiovascular (CV) risk related to lipid disorders is well established and is based on a robust body of evidence from well-designed randomized clinical trials, as well as prospective observational studies. In the last two decades, significant advances have been made in understanding the genetic basis of dyslipidemias. The present review is intended as a comprehensive discussion of current knowledge about the genetics and pathophysiology of disorders that predispose to dyslipidemia. We also focus on issues related to statins and the proprotein convertase subtilisin/kexin type 9 (PCSK9) and some of its polymorphisms, as well as new cholesterol-lowering medications, including PCSK9 inhibitors. Recent finding Cholesterol is essential for the proper functioning of several body systems. However, dyslipidemia-especially elevated low-density lipoprotein (LDL-c) and triglyceride levels, as well as reduced lipoprotein lipase activity-is associated with an increased risk of coronary artery disease (CAD). High-density lipoprotein (HDL-c), however, seems to play a role as a risk marker rather than as a causal factor of the disease, as suggested by Mendelian randomization studies. Several polymorphisms in the lipoprotein lipase locus have been described and are associated with variations in the activity of this enzyme, producing high concentrations of triglycerides and increased risk of CAD. Dyslipidemia, especially increased LDL-c and triglyceride levels, continues…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Spaceflight induced dyslipidemia in mice and astronauts (Schmidt et al., 2020) can be one contributor to cardiovascular health risks during longer-term space missions (Stein et al., 2019).”
From Comprehensive Multi-omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact (2020) · cites this paper as Stein et al., 2019
In the citing paper
“cardiovascular risk is related to lipid disorders (Stein et al., 2019) and associations between dysregulation of mitochondrial energy metabolism and poor cardiac health are common (Meyers et al., 2013).”
From Comprehensive Multi-omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact (2020) · cites this paper as Stein et al., 2019
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Cited by
da Silveira, W. A., Fazelinia, H., Rosenthal, S. B., Laiakis, E. C., Kim, M. S., Meydan, C., Kidane, Y., Rathi, K. S., Smith, S. M., Stear, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.002 · Cited by 402
“, 2020) can be one contributor to cardiovascular health risks during longer-term space missions (Stein et al., 2019).”
Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care · doi:10.2337/dc18-1491 · Cited by 117
Silva, M. L., Bernardo, A., Singh, J., & de Mesquita, M. F. (2022) · Nutrients · doi:10.3390/nu14132773 · Cited by 128
Si, Y., Fan, W., Han, C., Liu, J., & Sun, L. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.05.001 · Cited by 57
Modifiable Risk Factors for Cardiovascular Disease in Korea and Japan
Arafa, A., Lee, H., Eshak, E. S., Shirai, K., Liu, K., Li, J., Anni, N. S., Shim, S. Y., Kim, H. C., & Iso, H. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0121 · Cited by 54
Metadata
- Authors
- Stein, R., Ferrari, F., & Scolari, F.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Corresponding author
- Stein, Ricardo
- Venue
- Current Cardiology Reports
- Published
- 2019-06-21
- Volume
- 21
- Issue
- 8
- Pages
- 68-68
- ISSN
- 1523-3782 (ISSN-L)
- 1534-3170
- OpenAlex
- W2951317411
- Cited by
- 83
- References
- 109
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 12 · 2021: 13 · 2020: 11 · 2019: 1
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Current Cardiology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- dyslipidemia, cardiovascular disease, PCSK9, PCSK9 inhibitors, statins, LDL cholesterol, triglycerides, HDL cholesterol, coronary artery disease, primary prevention, Mendelian randomization
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Cardiovascular Diseases, Humans, Lipoproteins, LDL, Cholesterol, LDL, Mutation, Prospective Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. https://app.cochat.ai/papers/10.1007/s11886-019-1161-5
- The paper
- Stein, R., Ferrari, F., & Scolari, F. (2019). Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. Current Cardiology Reports. https://doi.org/10.1007/s11886-019-1161-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.